Literature DB >> 16585202

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.

Martina Bazzaro1, Michael K Lee, Alessia Zoso, Wanda L H Stirling, Antonio Santillan, Ie-Ming Shih, Richard B S Roden.   

Abstract

The ubiquitin-proteasome system (UPS) mediates targeted protein degradation. Notably, the UPS determines levels of key checkpoint proteins controlling apoptosis and proliferation by controlling protein half-life. Herein, we show that ovarian carcinoma manifests an overstressed UPS by comparison with normal tissues by accumulation of ubiquitinated proteins despite elevated proteasome levels. Elevated levels of total ubiquitinated proteins and 19S and 20S proteasome subunits are evident in both low-grade and high-grade ovarian carcinoma tissues relative to benign ovarian tumors and in ovarian carcinoma cell lines relative to immortalized surface epithelium. We find that ovarian carcinoma cell lines exhibit greater sensitivity to apoptosis in response to proteasome inhibitors than immortalized ovarian surface epithelial cells. This sensitivity correlates with increased cellular proliferation rate and UPS stress rather than absolute proteasome levels. Proteasomal inhibition in vitro induces cell cycle arrest and the accumulation of p21 and p27 and triggers apoptosis via activation of caspase-3. Furthermore, treatment with the licensed proteasome inhibitor PS-341 slows the growth of ES-2 ovarian carcinoma xenograft in immunodeficient mice. In sum, elevated proliferation and metabolic rate resulting from malignant transformation of the epithelium stresses the UPS and renders ovarian carcinoma more sensitive to apoptosis in response to proteasomal inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585202     DOI: 10.1158/0008-5472.CAN-05-2321

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.

Authors:  A Chiaviello; I Paciello; I Postiglione; E Crescenzi; G Palumbo
Journal:  Cell Prolif       Date:  2010-10       Impact factor: 6.831

2.  α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

Authors:  Martina Bazzaro; Ravi K Anchoori; Mohana Krishna R Mudiam; Olga Issaenko; Srinivas Kumar; Balasubramanyam Karanam; Zhenhua Lin; Rachel Isaksson Vogel; Riccardo Gavioli; Federica Destro; Valeria Ferretti; Richard B S Roden; Saeed R Khan
Journal:  J Med Chem       Date:  2010-12-27       Impact factor: 7.446

3.  RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.

Authors:  Raffaele Hellweg; Ashley Mooneyham; Zenas Chang; Mihir Shetty; Edith Emmings; Yoshie Iizuka; Christopher Clark; Timothy Starr; Juan H Abrahante; Florian Schütz; Gottfried Konecny; Peter Argenta; Martina Bazzaro
Journal:  Horm Cancer       Date:  2018-06-27       Impact factor: 3.869

4.  Chaperone molecules concentrate together with the ubiquitin-proteasome system inside particulate cytoplasmic structures: possible role in metabolism of misfolded proteins.

Authors:  Alessandro Vanoli; Vittorio Necchi; Serena Barozzi; Rachele Manca; Alessandro Pecci; Enrico Solcia
Journal:  Histochem Cell Biol       Date:  2015-05-08       Impact factor: 4.304

5.  Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility.

Authors:  Martina Bazzaro; Antonio Santillan; Zhenhua Lin; Taylor Tang; Michael K Lee; Robert E Bristow; Ie-Ming Shih; Richard B S Roden
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

6.  Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.

Authors:  Danielle D Jandial; Salman Farshchi-Heydari; Christopher A Larson; Gregory I Elliott; Wolfgang J Wrasidlo; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.

Authors:  Zhenhua Lin; Martina Bazzaro; Mei-Cheng Wang; Kwun C Chan; Shiwen Peng; Richard B S Roden
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 8.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

9.  Polyubiquitinated proteins, proteasome, and glycogen characterize the particle-rich cytoplasmic structure (PaCS) of neoplastic and fetal cells.

Authors:  Vittorio Necchi; Patrizia Sommi; Agostina Vitali; Alessandro Vanoli; Anna Savoia; Vittorio Ricci; Enrico Solcia
Journal:  Histochem Cell Biol       Date:  2014-03-01       Impact factor: 4.304

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.